Talecris stock slips as demand for blood-plasma products wane

12/1/2009 | News & Observer (Raleigh, N.C.), The

Shares of Talecris, a maker of blood plasma-derived treatments for various immune disorders, dropped Monday by almost 20% since reaching a high in early November, amid concerns that the company won't be able to sustain its rising profit into the coming year. Analysts say the economic downturn could create an oversupply in blood-plasma products as more people donate.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN